Delayed ischemic stroke ten days after aluminum phosphide ingestion in a previously healthy 21-year-old Ethiopian woman: a case report Authors: Amanuel Mesfin Oljira, Segni Shube Hunduma, Dereje Gurmessa Geleta, Rabira Waktola Gonfa, Dawit Yosef Barkesa, Bisrat Abate Bekele, Eliab Negusse Reda, Dagim Weldegiorgis Fininsa, Aemon Berhane Fissha, Mathewos Tesfaye Yanore Published: 2026 ABSTRACT BackgroundAluminum phosphide poisoning is a highly lethal toxicologic emergency classically dominated by cardiovascular collapse. Delayed ischemic stroke after apparent clinical stabilization is exceptionally rare and mechanistically uncertain.Case presentationA 21-year-old previously healthy Ethiopian woman intentionally ingested five aluminum phosphide tablets. After early gastric lavage, she remained hemodynamically stable during the initial 24 hours and was discharged. Ten days after ingestion, she developed sudden right facial weakness, right hemiparesis, and mild dysarthria. On day 11, her National Institutes of Health Stroke Scale score was 11. Contrast-enhanced brain computed tomography demonstrated acute-to-subacute hypodensity in the left lentiform nucleus, caudate head, and anterior limb of the internal capsule. Non-dedicated post-contrast computed tomography showed visual luminal asymmetry/narrowing of the left middle cerebral artery compared with the contralateral side. Evaluation with electrocardiography, 72-hour continuous inpatient telemetry, transthoracic echocardiography with agitated saline study, carotid/vertebral Doppler ultrasonography, cerebrospinal fluid analysis including acid-fast bacilli testing and GeneXpert, human immunodeficiency virus testing, tuberculosis screening, antiphospholipid antibodies repeated at 12 weeks, thrombophilia testing, and autoimmune markers did not identify an alternative cause within the limits of available investigations. Cerebrospinal fluid culture for tuberculosis and other bacteria, computed tomography angiography/magnetic resonance angiography, transcranial Doppler, serial vascular imaging, and prolonged outpatient Holter monitoring were unavailable. She received aspirin, venous thromboembolism prophylaxis, later atorvastatin 80 mg orally once daily, and structured rehabilitation. The modified Rankin Scale score improved from 4 at the 30-day functional assessment to 2 at three and six months.ConclusionsThis case describes delayed deep MCA-territory ischemic stroke temporally associated with aluminum phosphide ingestion. The observed computed tomography (CT) luminal asymmetry is hypothesis-generating only and cannot distinguish toxin-associated vasospasm/arteriopathy from reversible cerebral vasoconstriction syndrome, inflammatory vasculopathy, dissection-related disease, or pseudostenosis artifact. Clinicians should maintain vigilance for delayed focal neurologic deficits after aluminum phosphide exposure and pursue neuroimaging and etiologic evaluation, including dedicated vascular studies and follow-up vascular imaging where available.Key clinical messageDelayed focal ischemic stroke may occur after apparent clinical stabilization following aluminum phosphide ingestion, even without early hemodynamic collapse or structural heart disease. New lateralizing neurologic deficits after phosphide exposure should prompt urgent neuroimaging and structured young-stroke evaluation. In this case, the association with aluminum phosphide remains temporal and biologically plausible but not causal or mechanistically proven, because dedicated vascular imaging, serial angiography, and follow-up vascular imaging were unavailable.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13256-026-06403-2. Background Aluminum phosphide (AlP) is a solid fumigant widely used for grain storage in many low- and middle-income countries; its low cost and easy accessibility have made it a major agent of deliberate self-poisoning. In Ethiopia, a 2025 systematic review and meta-analysis reported a high burden of metallophosphide poisoning among poisoning admissions and substantial mortality [1]. Following ingestion, AlP reacts with gastric moisture and hydrochloric acid to release phosphine gas, which inhibits cytochrome c oxidase, depletes adenosine triphosphate, and generates reactive oxygen species, producing multisystem injury [2, 3]. The typical clinical course is dominated by gastrointestinal irritation, cardiovascular collapse, refractory hypotension, arrhythmias, and respiratory failure within hours. [1, 4] Neurologic complications are less common than cardiovascular manifestations, and delayed focal ischemic stroke after apparent stabilization has been reported only rarely [5–7]. We report a previously healthy young Ethiopian woman who developed delayed deep left MCA/lenticulostriate territory infarction ten days after AlP ingestion. The case is presented in accordance with the CAse REport(CARE)guideline [8]. The diagnostic and mechanistic interpretation is deliberately cautious: no alternative etiology was identified within available testing, but several important differentials could not be formally excluded because of resource limitations. Case presentation Patient information A 21-year-old previously healthy Ethiopian woman of Oromo ethnicity presented after intentional ingestion of five TANPHOS aluminum phosphide tablets, each containing 1.68 g AlP, for a total dose of 8.4 g dissolved in approximately 250 mL water (Fig. 1). This was her first self-harm episode. She had no personal or family history of hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, human immunodefi ciency virus (HIV) infection, autoimmune or rheumatologic disease, migraine, prior stroke or transient ischemic attack, cardiac disease, arrhythmia, or thromboembolism. She had never used oral contraceptive pills, tobacco, alcohol, or khat.Fig. 1TANPHOS aluminum phosphide product container as presented by the patient. Each tablet contains 1.68 g of aluminum phosphide; five tablets were ingested, for a total dose of 8.4 g dissolved in approximately 250 mL water. Patient consent was obtained for publication of this image TANPHOS aluminum phosphide product container as presented by the patient. Each tablet contains 1.68 g of aluminum phosphide; five tablets were ingested, for a total dose of 8.4 g dissolved in approximately 250 mL water. Patient consent was obtained for publication of this image Clinical findings and timeline The complete timeline of clinical events is presented in Table 1. Ingestion occurred at 14:30 hours on day 0. Within minutes she developed epigastric burning pain and reached a nearby health center within approximately 10 minutes. Gastric lavage was performed approximately 15 minutes after ingestion, and a garlic-like odor consistent with phosphine gas was documented. She received one liter of normal saline with 5% dextrose over eight hours. No activated charcoal, oil-based decontamination, vasopressors, or mechanical ventilation were administered. She remained fully conscious, with Glasgow Coma Scale 15/15, and was hemodynamically and cardiopulmonary stable throughout the initial 24 hours before discharge. Table 1Timeline of clinical eventsTime from ingestionClinical eventDay 0, 14:30 hoursIntentional ingestion of 5 TANPHOS tablets (8.4 g AlP total) dissolved in approximately 250 mL water; epigastric pain within minutesDay 0, 14:40 hoursArrival at a nearby health center approximately 10 minutes post-ingestion; garlic-like odor noted; gastric lavage performed approximately 15 minutes post-ingestionDay 0, 0–24 hoursHemodynamically stable throughout; GCS 15/15; 1 L normal saline/5% dextrose over 8 hours; ECG normal; discharged at 24 hoursDays 1–9Entirely asymptomatic; no hospitalization or medical contactDay 10Sudden onset right facial weakness, right hemiparesis, and mild dysarthria; no fever, meningism, headache, thunderclap headache, seizure, or altered mental statusDay 11Referred to and presented at tertiary hospital; BP 122/74 mmHg, HR 82/minute, SpO2 97% room air; NIHSS 11Day 11, + 2 hoursContrast-enhanced brain CT: acute-to-subacute left lentiform nucleus/caudate head/anterior limb internal capsule hypodensity; left MCA visual luminal asymmetry/narrowing on post-contrast seriesHospital days 1–3Aspirin started; LMWH for VTE prophylaxis; continuous inpatient telemetry for 72 hours showed no AF/AFL or other dysrhythmiaHospital day 2TTE: LVEF 64%, no PFO, thrombus, or valvular disease; Doppler: normal extracranial vasculature in visualized segments; thrombophilia, vasculitis, and aPL panels sent; CSF AFB and GeneXpert negative; HIV and TB screening negativeHospital day 5Dysphagia resolved; swallowing normalized on clinical assessmentHospital day 8Right-sided power improved to 3/5; mild dysarthria resolved; NIHSS 5Hospital day 10/day 20Discharged: right arm/leg 3/5, facial weakness and dysarthria resolved, hemiparetic gait; Barthel Index 65/100; NIHSS 4; mRS 330-day functional assessment/windowWheelchair-dependent in community, partial self-care, not returned to prior activities; mRS 4; no recurrent TIA/stroke reported2-week FU post-discharge/day 34Right power 4/5; NIHSS 2; BP and LDL-C normal; no TIA/stroke recurrence; no headache or thunderclap headache; aspirin taken consistently and tolerated6-week FU/day 51Right power 4/5 sustained; improving mobility; NIHSS 2; BP normal; no recurrence; atorvastatin 80 mg orally once daily later introduced and tolerated3-month FURight power 4/5; walking independently with hemiparetic gait; NIHSS 2; mRS 2; LDL-C and BP normal; no recurrence6-month FURight power 4/5; fully ambulatory with hemiparetic gait; NIHSS 2; mRS 2; LDL-C and BP normal; aPL confirmed negative on repeat; no recurrence; ongoing rehabilitation and psychotherapy; follow-up CT/CTA/MRA/TCD not performed because of financial constraintsAF/AFL atrial fibrillation/atrial flutter, AlP aluminum phosphide, aPL antiphospholipid antibodies, BP blood pressure, CSF cerebrospinal fluid, FU follow-up, CTA computed tomography angiography, MRA magnetic resonance angiography, GCS Glasgow Coma Scale, HR heart rate, LDL-C low-density lipoprotein cholesterol, LMWH low-molecular-weight heparin, LVEF left ventricular ejection fraction, MCA middle cerebral artery, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, PFO patent foramen ovale, SpO2 oxygen saturation, TIA transient ischemic attack, TTE transthoracic echocardiography, VTE venous thromboembolism Table 1Timeline of clinical eventsTime from ingestionClinical eventDay 0, 14:30 hoursIntentional ingestion of 5 TANPHOS tablets (8.4 g AlP total) dissolved in approximately 250 mL water; epigastric pain within minutesDay 0, 14:40 hoursArrival at a nearby health center approximately 10 minutes post-ingestion; garlic-like odor noted; gastric lavage performed approximately 15 minutes post-ingestionDay 0, 0–24 hoursHemodynamically stable throughout; GCS 15/15; 1 L normal saline/5% dextrose over 8 hours; ECG normal; discharged at 24 hoursDays 1–9Entirely asymptomatic; no hospitalization or medical contactDay 10Sudden onset right facial weakness, right hemiparesis, and mild dysarthria; no fever, meningism, headache, thunderclap headache, seizure, or altered mental statusDay 11Referred to and presented at tertiary hospital; BP 122/74 mmHg, HR 82/minute, SpO2 97% room air; NIHSS 11Day 11, + 2 hoursContrast-enhanced brain CT: acute-to-subacute left lentiform nucleus/caudate head/anterior limb internal capsule hypodensity; left MCA visual luminal asymmetry/narrowing on post-contrast seriesHospital days 1–3Aspirin started; LMWH for VTE prophylaxis; continuous inpatient telemetry for 72 hours showed no AF/AFL or other dysrhythmiaHospital day 2TTE: LVEF 64%, no PFO, thrombus, or valvular disease; Doppler: normal extracranial vasculature in visualized segments; thrombophilia, vasculitis, and aPL panels sent; CSF AFB and GeneXpert negative; HIV and TB screening negativeHospital day 5Dysphagia resolved; swallowing normalized on clinical assessmentHospital day 8Right-sided power improved to 3/5; mild dysarthria resolved; NIHSS 5Hospital day 10/day 20Discharged: right arm/leg 3/5, facial weakness and dysarthria resolved, hemiparetic gait; Barthel Index 65/100; NIHSS 4; mRS 330-day functional assessment/windowWheelchair-dependent in community, partial self-care, not returned to prior activities; mRS 4; no recurrent TIA/stroke reported2-week FU post-discharge/day 34Right power 4/5; NIHSS 2; BP and LDL-C normal; no TIA/stroke recurrence; no headache or thunderclap headache; aspirin taken consistently and tolerated6-week FU/day 51Right power 4/5 sustained; improving mobility; NIHSS 2; BP normal; no recurrence; atorvastatin 80 mg orally once daily later introduced and tolerated3-month FURight power 4/5; walking independently with hemiparetic gait; NIHSS 2; mRS 2; LDL-C and BP normal; no recurrence6-month FURight power 4/5; fully ambulatory with hemiparetic gait; NIHSS 2; mRS 2; LDL-C and BP normal; aPL confirmed negative on repeat; no recurrence; ongoing rehabilitation and psychotherapy; follow-up CT/CTA/MRA/TCD not performed because of financial constraintsAF/AFL atrial fibrillation/atrial flutter, AlP aluminum phosphide, aPL antiphospholipid antibodies, BP blood pressure, CSF cerebrospinal fluid, FU follow-up, CTA computed tomography angiography, MRA magnetic resonance angiography, GCS Glasgow Coma Scale, HR heart rate, LDL-C low-density lipoprotein cholesterol, LMWH low-molecular-weight heparin, LVEF left ventricular ejection fraction, MCA middle cerebral artery, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, PFO patent foramen ovale, SpO2 oxygen saturation, TIA transient ischemic attack, TTE transthoracic echocardiography, VTE venous thromboembolism Timeline of clinical events AF/AFL atrial fibrillation/atrial flutter, AlP aluminum phosphide, aPL antiphospholipid antibodies, BP blood pressure, CSF cerebrospinal fluid, FU follow-up, CTA computed tomography angiography, MRA magnetic resonance angiography, GCS Glasgow Coma Scale, HR heart rate, LDL-C low-density lipoprotein cholesterol, LMWH low-molecular-weight heparin, LVEF left ventricular ejection fraction, MCA middle cerebral artery, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, PFO patent foramen ovale, SpO2 oxygen saturation, TIA transient ischemic attack, TTE transthoracic echocardiography, VTE venous thromboembolism She remained asymptomatic from days 1 to 9. On day 10 she developed sudden right facial weakness, right upper- and lower-limb weakness, and mild dysarthria. There was no fever, meningism, headache, thunderclap headache, seizure, or altered mental status. On arrival at our tertiary hospital on day 11, blood pressure was 122/74 mmHg, heart rate 82/minute, respiratory rate 18/minute, temperature 36.8 °C, and oxygen saturation 97% on room air. Neurologic examination showed right upper motor neuron facial palsy, right arm and leg power 1/5, mild dysarthria, preserved language, no visual field deficit, no hemisensory loss, and no neglect. Admission NIHSS was 11. Diagnostic assessment Laboratory investigations at presentation are summarized in Table 2. Electrolytes, liver function tests, non-LDL lipid parameters, glucose, blood urea nitrogen, calcium, and magnesium were within reference ranges; only diagnostically relevant laboratory values are presented in Table 2 for conciseness. Creatinine, troponin I, coagulation profile, D-dimer, fibrinogen, HbA1c, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), antinuclear antibody (ANA), antineutrophil cytoplasmic antibody (ANCA), thrombophilia panel, sickling test, and urine human chorionic gonadotropin (hCG) were not suggestive of an alternative metabolic, systemic autoimmune, hypercoagulable, antiphospholipid, or hemoglobinopathy-related mechanism. Antiphospholipid antibodies were negative acutely and again at 12-week repeat testing, supporting exclusion of antiphospholipid syndrome by laboratory criteria. Table 2Diagnostically relevant laboratory, infectious, inflammatory, coagulation, thrombophilia, and vascular-risk investigationsPanelTestResultReference rangeInterpretationPregnancyUrine hCGNegativeNegative if non-pregnantNormalComplete blood countWBC9.1 × 103/µL3.9–11.7 × 103/µLNormalComplete blood countHemoglobin13.2 g/dL12.0–15.0 g/dLNormalComplete blood countPlatelets178 × 103/µL150–400 × 103/µLNormalRenal functionCreatinine0.75 mg/dL0.5–1.1 mg/dLNormalCardiac injuryTroponin I < 0.03 ng/mL ≤ 0.04 ng/mLNormalCoagulationPT12.3 seconds9.5–13.0 secondsNormalCoagulationINR1.20.8–1.2Upper-normalCoagulationaPTT30 seconds25–37 secondsNormalCoagulationD-dimer400 ng/mL < 500 ng/mLNormalCoagulationFibrinogen350 mg/dL200–400 mg/dLNormalVascular riskLDL-C70 mg/dL < 100 mg/dLOptimalVascular riskHbA1c4.9%4.0–5.9%NormalInflammatory markersESR10 mm/hour0–20 mm/hourNormalInflammatory markersCRP1.5 mg/L0.08–3.1 mg/LNormalAutoimmune/vasculitisANANegativeNegative/≤ 1:40NormalAutoimmune/vasculitisANCANegativeNegativeNormalAntiphospholipid syndromeaPL, acute phaseNegativeNegativeNormalAntiphospholipid syndromeaPL, 12-week repeatNegativeNegativeConfirmed negativeInherited thrombophiliaProtein C activity75%70–140%NormalInherited thrombophiliaProtein S activity82%60–140%NormalInherited thrombophiliaAntithrombin III91%80–120%NormalInherited thrombophiliaHomocysteine7.5 µmol/L5–15 µmol/LNormalHemoglobinopathySickling testNegativeNegative, HbS absentSickle cell disease less supportedInfectious/CSFCSF AFBNegativeNegativeTB meningitis less supportedInfectious/CSFCSF GeneXpertNegativeNegativeTB meningitis less supportedInfectiousHIV testingNegativeNegativeNo evidence of HIV infectionInfectiousTB screeningNegativeNegativeNo evidence from available screeningMicrobiology limitationCSF culture for TB and other bacteriaNot performed–Unavailable in our settingAFB acid-fast bacilli, ANA antinuclear antibody, ANCA antineutrophil cytoplasmic antibody, aPL antiphospholipid antibodies, aPTT activated partial thromboplastin time, CRP C-reactive protein, CSF cerebrospinal fluid, ESR erythrocyte sedimentation rate, HbA1c glycated hemoglobin, hCG human chorionic gonadotropin, HIV human immunodeficiency virus, INR international normalized ratio, LDL-C low-density lipoprotein cholesterol, PT prothrombin time, TB tuberculosis, WBC white blood cell count Table 2Diagnostically relevant laboratory, infectious, inflammatory, coagulation, thrombophilia, and vascular-risk investigationsPanelTestResultReference rangeInterpretationPregnancyUrine hCGNegativeNegative if non-pregnantNormalComplete blood countWBC9.1 × 103/µL3.9–11.7 × 103/µLNormalComplete blood countHemoglobin13.2 g/dL12.0–15.0 g/dLNormalComplete blood countPlatelets178 × 103/µL150–400 × 103/µLNormalRenal functionCreatinine0.75 mg/dL0.5–1.1 mg/dLNormalCardiac injuryTroponin I < 0.03 ng/mL ≤ 0.04 ng/mLNormalCoagulationPT12.3 seconds9.5–13.0 secondsNormalCoagulationINR1.20.8–1.2Upper-normalCoagulationaPTT30 seconds25–37 secondsNormalCoagulationD-dimer400 ng/mL < 500 ng/mLNormalCoagulationFibrinogen350 mg/dL200–400 mg/dLNormalVascular riskLDL-C70 mg/dL < 100 mg/dLOptimalVascular riskHbA1c4.9%4.0–5.9%NormalInflammatory markersESR10 mm/hour0–20 mm/hourNormalInflammatory markersCRP1.5 mg/L0.08–3.1 mg/LNormalAutoimmune/vasculitisANANegativeNegative/≤ 1:40NormalAutoimmune/vasculitisANCANegativeNegativeNormalAntiphospholipid syndromeaPL, acute phaseNegativeNegativeNormalAntiphospholipid syndromeaPL, 12-week repeatNegativeNegativeConfirmed negativeInherited thrombophiliaProtein C activity75%70–140%NormalInherited thrombophiliaProtein S activity82%60–140%NormalInherited thrombophiliaAntithrombin III91%80–120%NormalInherited thrombophiliaHomocysteine7.5 µmol/L5–15 µmol/LNormalHemoglobinopathySickling testNegativeNegative, HbS absentSickle cell disease less supportedInfectious/CSFCSF AFBNegativeNegativeTB meningitis less supportedInfectious/CSFCSF GeneXpertNegativeNegativeTB meningitis less supportedInfectiousHIV testingNegativeNegativeNo evidence of HIV infectionInfectiousTB screeningNegativeNegativeNo evidence from available screeningMicrobiology limitationCSF culture for TB and other bacteriaNot performed–Unavailable in our settingAFB acid-fast bacilli, ANA antinuclear antibody, ANCA antineutrophil cytoplasmic antibody, aPL antiphospholipid antibodies, aPTT activated partial thromboplastin time, CRP C-reactive protein, CSF cerebrospinal fluid, ESR erythrocyte sedimentation rate, HbA1c glycated hemoglobin, hCG human chorionic gonadotropin, HIV human immunodeficiency virus, INR international normalized ratio, LDL-C low-density lipoprotein cholesterol, PT prothrombin time, TB tuberculosis, WBC white blood cell count Diagnostically relevant laboratory, infectious, inflammatory, coagulation, thrombophilia, and vascular-risk investigations AFB acid-fast bacilli, ANA antinuclear antibody, ANCA antineutrophil cytoplasmic antibody, aPL antiphospholipid antibodies, aPTT activated partial thromboplastin time, CRP C-reactive protein, CSF cerebrospinal fluid, ESR erythrocyte sedimentation rate, HbA1c glycated hemoglobin, hCG human chorionic gonadotropin, HIV human immunodeficiency virus, INR international normalized ratio, LDL-C low-density lipoprotein cholesterol, PT prothrombin time, TB tuberculosis, WBC white blood cell count Because infectious/inflammatory vasculopathy was considered, cerebrospinal fluid analysis was performed. CSF acid-fast bacilli testing and GeneXpert were negative. HIV testing and tuberculosis screening were also negative. CSF culture for tuberculosis and other bacteria was not performed because it was unavailable in our setting. Therefore, tuberculous meningitis-associated vasculitis and other infectious meningitis-related vasculopathies were considered less clinically supported but not absolutely excluded. Cardiac and vascular evaluation A 12-lead electrocardiogram (ECG) obtained after admission demonstrated normal sinus rhythm at 80 beats per minute, QTc 420 microseconds, and no ectopy, conduction abnormality, or ST-T abnormality (Fig. 2). The patient underwent continuous inpatient telemetry from admission through 72 hours to screen for occult atrial fibrillation and other dysrhythmias; no atrial fibrillation or atrial flutter was detected. Prolonged outpatient Holter monitoring was unavailable.Fig. 2Cardiac investigations. Upper panel: 12-lead electrocardiogram obtained after admission demonstrating normal sinus rhythm at 80 beats per minute, normal frontal axis, normal QRS morphology, normal ST-T morphology, and QTc 420 microseconds, with no ectopy or conduction abnormality. Lower panel: representative transthoracic echocardiography image demonstrating normal biventricular systolic function ( left ventricular ejection fraction 64%), no regional wall-motion abnormality, no intracardiac thrombus, and no structural valvular disease. The agitated saline study was negative for intracardiac right-to-left shunt and patent foramen ovale under resting and Valsalva manoeuvre conditions Cardiac investigations. Upper panel: 12-lead electrocardiogram obtained after admission demonstrating normal sinus rhythm at 80 beats per minute, normal frontal axis, normal QRS morphology, normal ST-T morphology, and QTc 420 microseconds, with no ectopy or conduction abnormality. Lower panel: representative transthoracic echocardiography image demonstrating normal biventricular systolic function ( left ventricular ejection fraction 64%), no regional wall-motion abnormality, no intracardiac thrombus, and no structural valvular disease. The agitated saline study was negative for intracardiac right-to-left shunt and patent foramen ovale under resting and Valsalva manoeuvre conditions Transthoracic echocardiography showed left ventricular ejection fraction 64%, no wall-motion abnormality, no intracardiac thrombus, no valvular disease, normal left atrial size, and a negative agitated saline study for intracardiac shunt and patent foramen ovale under resting and Valsalva manoeuvre conditions. (Fig. 2). Carotid and vertebral Doppler ultrasonography was normal in the visualized cervical segments, but this does not definitively exclude high-cervical/skull-base internal carotid artery disease, subtle dissection, intracranial arteriopathy, or perforator pathology. Modern young-stroke frameworks emphasize dedicated intracranial and extracranial vascular imaging where available. computed tomography angiography/magnetic resonance angiography head and neck, transcranial Doppler, catheter angiography, and follow-up vascular imaging were not performed because they were unavailable or unaffordable for the patient. Neuroimaging Contrast-enhanced brain CT performed on day 11 showed acute-to-subacute hypodensity involving the left lentiform nucleus, left caudate head, and anterior limb of the left internal capsule, consistent with deep left MCA/lenticulostriate territory infarction (Fig. 3). Post-contrast images showed visual luminal asymmetry/narrowing of the left MCA compared with the right (Fig. 3). This was not a dedicated vascular study. Pseudostenosis artifact refers to apparent arterial narrowing on non-dedicated vascular CT caused by contrast timing, vessel orientation, partial-volume averaging, or suboptimal arterial opacification rather than true luminal stenosis. Therefore, the imaging finding was treated as hypothesis-generating only.Fig. 3Contrast-enhanced brain computed tomography. Pre-contrast images demonstrate hypodensity in the left lentiform nucleus, left caudate head, and anterior limb of the left internal capsule, consistent with acute-to-subacute deep left middle cerebral artery-territory infarction. Post-contrast images demonstrate visual luminal asymmetry/narrowing of the left middle cerebral artery compared with the contralateral side; because this was not a dedicated vascular study, true stenosis cannot be confirmed and pseudostenosis artifact remains possible Contrast-enhanced brain computed tomography. Pre-contrast images demonstrate hypodensity in the left lentiform nucleus, left caudate head, and anterior limb of the left internal capsule, consistent with acute-to-subacute deep left middle cerebral artery-territory infarction. Post-contrast images demonstrate visual luminal asymmetry/narrowing of the left middle cerebral artery compared with the contralateral side; because this was not a dedicated vascular study, true stenosis cannot be confirmed and pseudostenosis artifact remains possible Etiologic classification The stroke was classified as ischemic stroke of undetermined etiology/cryptogenic within the limits of available investigations and temporally associated with AlP ingestion. The available evidence does not establish causality. The etiologic evaluation and residual uncertainty are summarized in Table 3. The non-dedicated CT luminal asymmetry cannot distinguish true arteriopathy, vasospasm, reversible cerebral vasoconstriction syndrome, inflammatory vasculopathy including tuberculous meningitis-associated vasculitis, dissection-related disease, or artifact. Table 3Young-stroke etiologic evaluation and residual uncertaintyMechanism domainInvestigation (s)Result/interpretationResidual uncertainty/reviewer-facing clarificationCardioembolic—structuralTTE with agitated saline bubble study; troponin INormal; LVEF 64%; no PFO/right-to-left shunt; no intracardiac thrombus, wall-motion abnormality, or valvular disease; troponin I normalTEE was not performed; however, structural cardioembolism was not supported by available testingCardioembolic—arrhythmic12-lead ECG; continuous inpatient telemetry from admission through 72 hoursNormal sinus rhythm; QTc 420 microseconds; no AF/AFL or other dysrhythmia detected during 72-hour telemetryProlonged outpatient Holter/event monitoring was unavailable; intermittent paroxysmal arrhythmia cannot be excluded with absolute certaintyLarge-artery atherosclerosisLipid profile; HbA1c; carotid/vertebral Doppler ultrasonographyLDL-C 70 mg/dL; HbA1c 4.9%; Doppler normal in visualized cervical segmentsCTA/MRA head and neck were unavailable; intracranial or high-cervical disease cannot be fully excludedCervical artery dissection/high ICA diseaseCarotid/vertebral Doppler ultrasonographyNo plaque, stenosis, mural hematoma, or dissection features in visualized cervical segmentsDoppler cannot definitively exclude subtle dissection or high-cervical/skull-base ICA pathology; CTA/MRA unavailableIntracranial arteriopathy/vasospasmPost-contrast brain CT assessment of MCA caliberVisual left MCA luminal asymmetry/narrowing on non-dedicated post-contrast CTThis is hypothesis-generating only; CTA/MRA/TCD/catheter angiography and follow-up vascular imaging were unavailable, so true stenosis, vasospasm, RCVS, inflammatory vasculopathy, dissection-related disease, or pseudostenosis artifact cannot be distinguishedReversible cerebral vasoconstriction syndromeClinical history for headache/thunderclap headache; CT reviewNo headache or thunderclap headache reported; no recurrence during follow-upRCVS cannot be formally excluded without dedicated angiographic imaging and serial follow-up showing reversibility/resolutionInfectious/inflammatory vasculitis including TB meningitisClinical assessment; HIV testing; TB screening; CSF analysis including AFB and GeneXpertNo fever, meningism, headache, seizure, or altered mental status; HIV and TB screening negative; CSF AFB and GeneXpert negativeCSF culture for TB and other bacteria was unavailable; infectious meningitis-related vasculopathy is less supported but not absolutely excludedVasculitis/autoimmuneANA; ANCA; ESR; CRPANA and ANCA negative; ESR 10 mm/hour; CRP 1.5 mg/LNormal inflammatory markers reduce support but do not independently exclude all CNS inflammatory vasculopathiesCoagulopathy/DICPT/INR; aPTT; fibrinogen; D-dimer; platelet countAll within normal limits; no laboratory evidence of coagulopathy or DICNo residual major uncertainty from available coagulation profileInherited thrombophiliaProtein C activity; Protein S activity; antithrombin III; homocysteineAll within reference rangeExpanded genetic thrombophilia testing was not reportedAntiphospholipid syndromeaCL IgG/IgM; lupus anticoagulant; anti-β2GP1 IgG/IgM in acute phase and repeated at 12 weeksNegative on both occasions; APS not supported by laboratory criteriaNo residual major uncertainty for APS based on available repeated testingPFO/intracardiac shuntTTE with agitated saline study at rest and ValsalvaNo shunt; no PFO identifiedTEE was unavailable; clinically significant PFO is unlikely but not assessed with TEEHematologic/hemoglobinopathyFull blood count; sickling testNormal hemoglobin and platelet count; sickling test negativeHemoglobin electrophoresis was not reported; sickle cell disease less supportedMetabolic vascular riskHbA1c; LDL-C; blood pressure at presentation and follow-upHbA1c normal; LDL-C normal/optimal; blood pressure normal throughout follow-upConventional metabolic vascular risk was not supportedToxic/metabolic endothelial injury after AlPExposure history; temporal association; negative workup within available resourcesDelayed stroke occurred 10 days after confirmed AlP ingestion; no alternative etiology identified within available investigationsBiologically plausible but unproven; causality cannot be inferred from a single case reportImaging artifact/pseudostenosisReview of non-dedicated post-contrast CTVisual MCA asymmetry notedPseudostenosis artifact remains possible because dedicated vascular imaging was unavailableAFB acid-fast bacilli, AF/AFL atrial fibrillation/atrial flutter, ANA antinuclear antibody, ANCA antineutrophil cytoplasmic antibody, aCL anticardiolipin antibody, aPTT activated partial thromboplastin time, APS antiphospholipid syndrome, CRP C-reactive protein, CTA CT angiography, DIC disseminated intravascular coagulation, ESR erythrocyte sedimentation rate, HbA1c glycated hemoglobin, ICA internal carotid artery, LDL-C low-density lipoprotein cholesterol, LVEF left ventricular ejection fraction, MCA middle cerebral artery, MRA MR angiography, PFO patent foramen ovale, RCVS reversible cerebral vasoconstriction syndrome, TB tuberculosis, TCD transcranial Doppler, TEE transesophageal echocardiography, TTE transthoracic echocardiography Table 3Young-stroke etiologic evaluation and residual uncertaintyMechanism domainInvestigation (s)Result/interpretationResidual uncertainty/reviewer-facing clarificationCardioembolic—structuralTTE with agitated saline bubble study; troponin INormal; LVEF 64%; no PFO/right-to-left shunt; no intracardiac thrombus, wall-motion abnormality, or valvular disease; troponin I normalTEE was not performed; however, structural cardioembolism was not supported by available testingCardioembolic—arrhythmic12-lead ECG; continuous inpatient telemetry from admission through 72 hoursNormal sinus rhythm; QTc 420 microseconds; no AF/AFL or other dysrhythmia detected during 72-hour telemetryProlonged outpatient Holter/event monitoring was unavailable; intermittent paroxysmal arrhythmia cannot be excluded with absolute certaintyLarge-artery atherosclerosisLipid profile; HbA1c; carotid/vertebral Doppler ultrasonographyLDL-C 70 mg/dL; HbA1c 4.9%; Doppler normal in visualized cervical segmentsCTA/MRA head and neck were unavailable; intracranial or high-cervical disease cannot be fully excludedCervical artery dissection/high ICA diseaseCarotid/vertebral Doppler ultrasonographyNo plaque, stenosis, mural hematoma, or dissection features in visualized cervical segmentsDoppler cannot definitively exclude subtle dissection or high-cervical/skull-base ICA pathology; CTA/MRA unavailableIntracranial arteriopathy/vasospasmPost-contrast brain CT assessment of MCA caliberVisual left MCA luminal asymmetry/narrowing on non-dedicated post-contrast CTThis is hypothesis-generating only; CTA/MRA/TCD/catheter angiography and follow-up vascular imaging were unavailable, so true stenosis, vasospasm, RCVS, inflammatory vasculopathy, dissection-related disease, or pseudostenosis artifact cannot be distinguishedReversible cerebral vasoconstriction syndromeClinical history for headache/thunderclap headache; CT reviewNo headache or thunderclap headache reported; no recurrence during follow-upRCVS cannot be formally excluded without dedicated angiographic imaging and serial follow-up showing reversibility/resolutionInfectious/inflammatory vasculitis including TB meningitisClinical assessment; HIV testing; TB screening; CSF analysis including AFB and GeneXpertNo fever, meningism, headache, seizure, or altered mental status; HIV and TB screening negative; CSF AFB and GeneXpert negativeCSF culture for TB and other bacteria was unavailable; infectious meningitis-related vasculopathy is less supported but not absolutely excludedVasculitis/autoimmuneANA; ANCA; ESR; CRPANA and ANCA negative; ESR 10 mm/hour; CRP 1.5 mg/LNormal inflammatory markers reduce support but do not independently exclude all CNS inflammatory vasculopathiesCoagulopathy/DICPT/INR; aPTT; fibrinogen; D-dimer; platelet countAll within normal limits; no laboratory evidence of coagulopathy or DICNo residual major uncertainty from available coagulation profileInherited thrombophiliaProtein C activity; Protein S activity; antithrombin III; homocysteineAll within reference rangeExpanded genetic thrombophilia testing was not reportedAntiphospholipid syndromeaCL IgG/IgM; lupus anticoagulant; anti-β2GP1 IgG/IgM in acute phase and repeated at 12 weeksNegative on both occasions; APS not supported by laboratory criteriaNo residual major uncertainty for APS based on available repeated testingPFO/intracardiac shuntTTE with agitated saline study at rest and ValsalvaNo shunt; no PFO identifiedTEE was unavailable; clinically significant PFO is unlikely but not assessed with TEEHematologic/hemoglobinopathyFull blood count; sickling testNormal hemoglobin and platelet count; sickling test negativeHemoglobin electrophoresis was not reported; sickle cell disease less supportedMetabolic vascular riskHbA1c; LDL-C; blood pressure at presentation and follow-upHbA1c normal; LDL-C normal/optimal; blood pressure normal throughout follow-upConventional metabolic vascular risk was not supportedToxic/metabolic endothelial injury after AlPExposure history; temporal association; negative workup within available resourcesDelayed stroke occurred 10 days after confirmed AlP ingestion; no alternative etiology identified within available investigationsBiologically plausible but unproven; causality cannot be inferred from a single case reportImaging artifact/pseudostenosisReview of non-dedicated post-contrast CTVisual MCA asymmetry notedPseudostenosis artifact remains possible because dedicated vascular imaging was unavailableAFB acid-fast bacilli, AF/AFL atrial fibrillation/atrial flutter, ANA antinuclear antibody, ANCA antineutrophil cytoplasmic antibody, aCL anticardiolipin antibody, aPTT activated partial thromboplastin time, APS antiphospholipid syndrome, CRP C-reactive protein, CTA CT angiography, DIC disseminated intravascular coagulation, ESR erythrocyte sedimentation rate, HbA1c glycated hemoglobin, ICA internal carotid artery, LDL-C low-density lipoprotein cholesterol, LVEF left ventricular ejection fraction, MCA middle cerebral artery, MRA MR angiography, PFO patent foramen ovale, RCVS reversible cerebral vasoconstriction syndrome, TB tuberculosis, TCD transcranial Doppler, TEE transesophageal echocardiography, TTE transthoracic echocardiography Young-stroke etiologic evaluation and residual uncertainty AFB acid-fast bacilli, AF/AFL atrial fibrillation/atrial flutter, ANA antinuclear antibody, ANCA antineutrophil cytoplasmic antibody, aCL anticardiolipin antibody, aPTT activated partial thromboplastin time, APS antiphospholipid syndrome, CRP C-reactive protein, CTA CT angiography, DIC disseminated intravascular coagulation, ESR erythrocyte sedimentation rate, HbA1c glycated hemoglobin, ICA internal carotid artery, LDL-C low-density lipoprotein cholesterol, LVEF left ventricular ejection fraction, MCA middle cerebral artery, MRA MR angiography, PFO patent foramen ovale, RCVS reversible cerebral vasoconstriction syndrome, TB tuberculosis, TCD transcranial Doppler, TEE transesophageal echocardiography, TTE transthoracic echocardiography Management and hospital course Because the patient presented approximately 24 hours after symptom onset, intravenous thrombolysis was not administered. Aspirin 325 mg was given as a loading dose followed by 81 mg orally once daily. Low-molecular-weight heparin 7500 IU subcutaneously twice daily was used for venous thromboembolism prophylaxis. Physiotherapy, occupational therapy, speech therapy, and psychiatric follow-up were initiated. Dysphagia resolved by hospital day 5. Right-sided power improved to 3/5 by hospital day 8 and dysarthria resolved. She was discharged on hospital day 10/day 20 from ingestion with NIHSS 4, mRS 3, Barthel index 65/100, right power 3/5, resolved facial weakness, resolved dysarthria, and hemiparetic gait. Atorvastatin 80 mg orally once daily was not initiated during the earliest inpatient decision-making because the treating team initially classified the stroke as non-atherosclerotic, low-density lipoprotein cholesterol was optimal at 70 mg/dL, and the patient was young without conventional vascular risk factors. During follow-up, atorvastatin 80 mg orally once daily was started and was tolerated. This management decision warrants cautious reflection because statins may have endothelial-stabilizing, anti-inflammatory, and antioxidative effects beyond lipid lowering, which could be relevant in ischemic stroke and in a hypothesized phosphine-related endothelial injury model. Follow-up and outcomes Outpatient neurologic, functional, and medication follow-up is summarized in Table 4. At the 30-day functional assessment/window, she was wheelchair-dependent in the community, partially caring for herself, and had not returned to prior activities (mRS 4). At the first outpatient review two weeks after discharge/day 34 from ingestion, right power improved to 4/5 and NIHSS was 2; blood pressure and LDL-C were normal, and she reported no recurrent TIA/stroke symptoms and no headache or thunderclap headache. Aspirin was taken consistently and tolerated without bleeding, dyspepsia, allergy, or other medication-related adverse effects. At 6 weeks/day 51, power remained 4/5 and NIHSS 2, with no recurrence. At 3 months, she walked independently with a hemiparetic gait, NIHSS 2, mRS 2, normal blood pressure, normal LDL-C, and no recurrence. At 6 months, she remained fully ambulatory with hemiparetic gait, NIHSS 2, mRS 2, normal blood pressure and LDL-C, repeat antiphospholipid antibodies were negative, and she continued rehabilitation and psychotherapy. Follow-up CT, CTA, MRA, or TCD was not performed because of financial constraints. Table 4Outpatient neurologic, functional, and medication outcome trajectoryTime pointNIHSSmRSMRC R arm/legMobility statusNotes30-day functional assessment/window4†43–4/5Wheelchair-dependent in communityPartial self-care; not returned to prior activities; no recurrent TIA/stroke reported2-week follow-up post-discharge, Day 34 from ingestion24, improving4/5/4/5Transitioning off wheelchairBP and LDL-C normal; no TIA/stroke recurrence; no headache or thunderclap headache; aspirin taken consistently and tolerated6-week follow-up, Day 51 from ingestion224/5/4/5Ambulatory with hemiparetic gaitBP normal; no recurrence; no new symptoms; atorvastatin 80 mg orally once daily later introduced and tolerated3-month follow-up224/5/4/5Independent ambulation with hemiparetic gaitLDL-C and BP normal; no recurrence6-month follow-up224/5/4/5Fully ambulatory with hemiparetic gaitaPL confirmed negative; LDL-C and BP normal; no recurrence; ongoing rehabilitation and psychotherapy; follow-up CT/CTA/MRA/TCD not performed because of financial constraints† NIHSS at the 30-day functional assessment was carried forward from discharge documentation where direct NIHSS reassessment was not available; power improved from 3/5 to 4/5 by day 34aPL antiphospholipid antibodies, BP blood pressure, CTA computed tomography angiography, FU follow-up, LDL-C low-density lipoprotein cholesterol, MRA magnetic resonance angiography, MRC Medical Research Council power scale, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, R right, TCD transcranial Doppler, TIA transient ischemic attack Table 4Outpatient neurologic, functional, and medication outcome trajectoryTime pointNIHSSmRSMRC R arm/legMobility statusNotes30-day functional assessment/window4†43–4/5Wheelchair-dependent in communityPartial self-care; not returned to prior activities; no recurrent TIA/stroke reported2-week follow-up post-discharge, Day 34 from ingestion24, improving4/5/4/5Transitioning off wheelchairBP and LDL-C normal; no TIA/stroke recurrence; no headache or thunderclap headache; aspirin taken consistently and tolerated6-week follow-up, Day 51 from ingestion224/5/4/5Ambulatory with hemiparetic gaitBP normal; no recurrence; no new symptoms; atorvastatin 80 mg orally once daily later introduced and tolerated3-month follow-up224/5/4/5Independent ambulation with hemiparetic gaitLDL-C and BP normal; no recurrence6-month follow-up224/5/4/5Fully ambulatory with hemiparetic gaitaPL confirmed negative; LDL-C and BP normal; no recurrence; ongoing rehabilitation and psychotherapy; follow-up CT/CTA/MRA/TCD not performed because of financial constraints† NIHSS at the 30-day functional assessment was carried forward from discharge documentation where direct NIHSS reassessment was not available; power improved from 3/5 to 4/5 by day 34aPL antiphospholipid antibodies, BP blood pressure, CTA computed tomography angiography, FU follow-up, LDL-C low-density lipoprotein cholesterol, MRA magnetic resonance angiography, MRC Medical Research Council power scale, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, R right, TCD transcranial Doppler, TIA transient ischemic attack Outpatient neurologic, functional, and medication outcome trajectory † NIHSS at the 30-day functional assessment was carried forward from discharge documentation where direct NIHSS reassessment was not available; power improved from 3/5 to 4/5 by day 34 aPL antiphospholipid antibodies, BP blood pressure, CTA computed tomography angiography, FU follow-up, LDL-C low-density lipoprotein cholesterol, MRA magnetic resonance angiography, MRC Medical Research Council power scale, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, R right, TCD transcranial Doppler, TIA transient ischemic attack Patient perspective “Surviving the ingestion only to wake up with one side of my body weakened and my speech changed was something I had not anticipated. The right side of my face was different, my arm and leg would not move as I wanted, and my words came out slurred. The slow process of regaining movement—day by day, visit by visit—gave me something to focus on alongside the psychiatric support I was receiving. Being able to walk independently at 6 months was a recovery I had doubted at the time I left the hospital.” Discussion This case is clinically notable because delayed deep MCA-territory ischemic stroke occurred ten days after AlP ingestion in a young woman who had no documented hemodynamic collapse, atrial fibrillation/flutter on 72-hour telemetry, cardiomyopathy, or conventional vascular risk factors during the acute phase; the absence of echocardiographic cardiomyopathy is relevant because myocardial dysfunction is a recognized prognostic feature in AlP poisoning [9, 10]. The case supports vigilance for delayed focal neurologic complications after phosphide exposure, but it does not prove causality. Several biologically plausible but unproven mechanisms may bridge AlP exposure and delayed focal ischemia. Phosphine inhibits mitochondrial cytochrome c oxidase, causes adenosine triphosphate (ATP) depletion, and generates reactive oxygen species [2, 3]. Oxidative stress may injure cerebral endothelium, impair nitric oxide-mediated vasodilation, promote vasospasm, activate platelets, and create a prothrombotic endothelial phenotype. In theory, these mechanisms could produce delayed localized vasospasm, perforator dysfunction, or microvascular microthrombi within lenticulostriate branches. Chemical endothelial injury may also evolve over days, providing a possible explanation for delayed onset. However, without CTA/MRA/TCD, serial vascular imaging, or histopathology, these mechanisms remain speculative. Broader AlP treatment literature remains focused on supportive care and investigational antidotal, antioxidant, decontamination, and metabolic strategies rather than delayed cerebrovascular prevention [11–15]. Reversible cerebral vasoconstriction syndrome (RCVS) is an important alternative mechanism in young adults with ischemic stroke and can be triggered by toxic or vasoactive exposures [16, 17]. Although thunderclap headache is typical, it may be absent, unreported, or not elicited. The absence of headache or thunderclap headache throughout follow-up lowers clinical support for RCVS but does not exclude it. RCVS cannot be formally excluded without dedicated angiographic imaging and follow-up imaging demonstrating reversibility or resolution of segmental vasoconstriction [18]. Tuberculous meningitis-associated vasculitis and other infectious meningitis-related inflammatory vasculopathies also require explicit consideration in this Ethiopian/sub-Saharan African context because tuberculous meningitis (TBM)-associated stroke commonly involves perforating arteries and deep structures including basal ganglia/internal capsule regions [19–21]. In this patient, the absence of fever, meningism, headache, seizure, altered mental status, or progressive neurologic decline; negative HIV and tuberculosis (TB) screening; negative CSF acid-fast bacilli (AFB) and GeneXpert; and functional improvement to modified Rankin Scale (mRS) 2 at six months without anti-tuberculous therapy all argue against active TB meningitis. However, because CSF culture for tuberculosis and other bacteria was unavailable, infectious meningitis-related vasculopathy cannot be excluded with absolute certainty. The visual MCA luminal asymmetry on post-contrast CT should therefore be interpreted cautiously. It may represent toxin-associated vasospasm or arteriopathy, but it may also reflect RCVS, inflammatory vasculopathy, dissection-related disease, or pseudostenosis artifact. Young-stroke phenotyping frameworks emphasize dedicated intracranial and extracranial vascular imaging and rhythm monitoring when available, especially for strokes of undetermined cause in young adults [17]. In this case, the arteriopathy hypothesis is hypothesis-generating only. Limitations This report has important limitations. Magnetic resonance imaging (MRI) with diffusion-weighted imaging was unavailable, so diagnosis rests on CT. CTA/MRA head and neck, transcranial Doppler, catheter angiography, serial vascular imaging, and follow-up CT were not performed; thus true arteriopathy, vasospasm, RCVS, inflammatory vasculopathy, subtle high-cervical/skull-base ICA disease, dissection, and pseudostenosis artifact could not be distinguished. CSF AFB and GeneXpert were negative, but CSF culture for tuberculosis and other bacteria was unavailable; therefore, tuberculous meningitis-associated vasculitis and other infectious meningitis-related vasculopathies cannot be excluded with absolute certainty. Continuous inpatient telemetry for 72 hours did not detect AF/AFL, but prolonged outpatient Holter monitoring was unavailable, leaving residual uncertainty about intermittent paroxysmal arrhythmia. Arterial blood gas and serum lactate were unavailable during the acute poisoning phase. Standardized rehabilitation scales beyond NIHSS, mRS, Barthel index, and Medical Research Council (MRC) power grading were not administered. Atorvastatin 80 mg orally once daily was started later rather than immediately, which should be interpreted in light of evolving management considerations. As a single case report, no causal inference can be drawn. Conclusion Delayed ischemic stroke can occur after apparent clinical stabilization following aluminum phosphide ingestion. In this patient, no alternative cause was identified within available investigations, but the mechanism remains uncertain. Visual MCA luminal narrowing on non-dedicated post-contrast CT is hypothesis-generating only and requires angiographic confirmation. Dedicated vascular imaging, serial vascular assessment, CSF microbiological studies where available, and prolonged rhythm monitoring are important to refine etiologic classification in similar young-stroke presentations. Teaching points Delayed focal ischemic stroke may occur after aluminum phosphide exposure even without early hemodynamic collapse; new lateralizing deficits should prompt urgent neuroimaging.A cryptogenic classification should be framed as “no cause identified within available investigations”, not as exclusion of all competing mechanisms.Visual arterial narrowing on non-dedicated post-contrast CT cannot confirm intracranial arteriopathy and may represent vasospasm, RCVS, inflammatory vasculopathy, dissection-related disease, or pseudostenosis artifact.In young adults, infectious vasculitis including tuberculous meningitis-associated vasculitis and RCVS should be explicitly considered; negative CSF AFB/GeneXpert lowers support for TBM but unavailable CSF culture prevents absolute exclusion.Structured rehabilitation may support meaningful recovery after deep MCA-territory infarction, but outcome observations from a single case remain descriptive. Delayed focal ischemic stroke may occur after aluminum phosphide exposure even without early hemodynamic collapse; new lateralizing deficits should prompt urgent neuroimaging. Delayed focal ischemic stroke may occur after aluminum phosphide exposure even without early hemodynamic collapse; new lateralizing deficits should prompt urgent neuroimaging. A cryptogenic classification should be framed as “no cause identified within available investigations”, not as exclusion of all competing mechanisms. A cryptogenic classification should be framed as “no cause identified within available investigations”, not as exclusion of all competing mechanisms. Visual arterial narrowing on non-dedicated post-contrast CT cannot confirm intracranial arteriopathy and may represent vasospasm, RCVS, inflammatory vasculopathy, dissection-related disease, or pseudostenosis artifact. Visual arterial narrowing on non-dedicated post-contrast CT cannot confirm intracranial arteriopathy and may represent vasospasm, RCVS, inflammatory vasculopathy, dissection-related disease, or pseudostenosis artifact. In young adults, infectious vasculitis including tuberculous meningitis-associated vasculitis and RCVS should be explicitly considered; negative CSF AFB/GeneXpert lowers support for TBM but unavailable CSF culture prevents absolute exclusion. In young adults, infectious vasculitis including tuberculous meningitis-associated vasculitis and RCVS should be explicitly considered; negative CSF AFB/GeneXpert lowers support for TBM but unavailable CSF culture prevents absolute exclusion. Structured rehabilitation may support meaningful recovery after deep MCA-territory infarction, but outcome observations from a single case remain descriptive. Structured rehabilitation may support meaningful recovery after deep MCA-territory infarction, but outcome observations from a single case remain descriptive. Supplementary Information Supplementary Material 1. Supplementary Material 1.